Investor Relations
Join us in transforming vision care for millions worldwide
Investment Highlights
Compelling opportunity backed by proven science and market demand
Proven Technology
Proprietary sdRNA platform with demonstrated efficacy and patent protection in key markets
Expert Team
World-class scientists, regulatory experts, and business leaders with proven track records
Clear Path Forward
Well-defined regulatory strategy and clinical development timeline to market
Funding & Milestones
Our journey of growth and achievement
Clinical Trial Enrollment Begins
Initiating patient enrollment for Phase I clinical trials. Interested in participating? Contact us.
$1M UBV Investment
UBV recognized as Project of the Year by LifeSciencesNY. UBV invested into DUB.
$2M NIH Grant Awarded
National Institutes of Health grant to advance sdRNA platform
NEI Awards $1.8M USD Grant
National Eye Institute funding to support sdRNA platform development in PCED
Patent Protection Secured
Exclusive licensing options in key international markets
Market Analytics
Data-driven insights into the ophthalmic therapeutics market opportunity
Global Ophthalmic Therapeutics Market Growth
Market size in billions USD (Historical data and projections through 2030)
Target Disease Distribution
Global patient population by condition (millions)
Development Progress
Current status towards clinical trials
Current Phase: Preclinical development complete, IND filing preparation underway
The Technology
Explore the mechanism of action behind our self-delivering RNA therapeutics
sdRNA Design & Synthesis
Our proprietary self-delivering RNA (sdRNA) molecules are designed to target specific genes involved in scarring and inflammation. The unique chemical modifications enable cellular uptake without the need for additional delivery vehicles.
Scientific Publications
Our research is backed by peer-reviewed publications and scientific validation
Silencing Ubiquitin-Specific Peptidase 10 Alleviates Persistent Corneal Epithelial Defect in Mice
Mitochondrial and Microtubule Defects in Exfoliation Glaucoma
Investor Resources
Seed Stage Investment Opportunity
Join us in revolutionizing ocular therapeutics
Seed stage closes Early Q1 2026
Confidential Investor Deck
Request access to our confidential investor deck with detailed financial projections, proprietary information, and comprehensive business strategy.